Omada Health, Inc. OMDA

Healthcare SIC 8000 - Services-Health Services Nasdaq

Our mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms. We deliver virtual care between doctor's visits, providing an engaging, personalized, and integrated experience for the individuals in our programs, which we call our "members." Our care is designed to improve their health while delivering value for the employers, health insurance companies ("health plans"), health systems, pharmacy benefit managers ("PBMs"), and other entities that cover the cost of our programs. Our platform is grounded in evidence and supported by peer-reviewed clinical research and third-party accreditations, which we believe enhances credibility with customers, our reseller partners, and other stakeholders. We differentiate through our human-led, technology-enabled care model, which combines proactive Care Teams with data-driven tools to deliver personalized support at scale. We call this approach Compassionate Intelligence. We work to develop trust with each member and use technology to help us personalize their experience, enabling us to unlock results at scale.

Last close 22.77 2026-09-04
Market cap $1.39B 2026-06-30 share count
52-week range 10.28 - 26.91

Valuation FY2025 figures against the last close

P/S5.4x
P/E
P/FCF82.3x
EV/EBITDA
Dividend yield
Diluted EPS-0.35

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022
Revenue $260.2M$169.8M$122.8M
Cost of revenue $89.3M$66.9M$52.8M
Gross profit $170.9M$102.9M$70.0M
R&D $40.7M$35.9M$33.7M
SG&A $52.2M$42.6M$36.0M
Total operating expenses $182.9M$146.5M$136.0M
Operating income -$12.0M-$43.7M-$66.0M
Interest expense $2.5M$4.5M$4.7M
Pre-tax income -$12.8M-$47.1M-$67.5M
Income tax $0$0$0
Net income -$12.8M-$47.1M-$67.5M
EPS, basic -0.35-6.11-9.52
EPS, diluted -0.35-6.11-9.52
Shares, diluted (wtd. avg.) $36.6M$7.7M$7.1M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022
Cash and equivalents $222.0M$76.4M$115.6M$168.1M
Receivables $34.6M$23.4M
Inventory $4.5M$3.3M
Total current assets $272.9M$113.1M
Property, plant and equipment $7.9M$5.6M
Goodwill $13.2M$13.2M
Other intangibles $2.4M$4.3M
Total assets $305.4M$150.9M
Accounts payable $10.3M$4.2M
Total current liabilities $75.7M$54.0M
Long-term debt $0$29.8M
Total liabilities $75.7M$86.3M
Retained earnings -$456.7M-$444.0M
Total equity $229.7M-$384.4M-$350.1M-$293.2M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022
Operating cash flow $18.3M-$34.2M-$49.7M
Depreciation and amortisation $5.5M$4.8M$4.4M
Stock-based compensation $13.0M$9.4M$8.7M
Capital expenditure $1.3M$596.0K$416.0K
Investing cash flow -$5.8M-$3.9M-$2.9M
Financing cash flow $133.2M-$1.2M$179.0K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-015637.

Others in SIC 8000

TickerCompanyMarket capP/ERevenue growth
LFST LifeStance Health Group, Inc. $4.86B 13.9%
PRVA Privia Health Group, Inc. $2.64B 114.8x 22.3%
WGS GeneDx Holdings Corp. $2.56B 40.0%
INNV InnovAge Holding Corp. $1.46B 11.8%
PNTG Pennant Group, Inc. $1.33B 45.2x 36.3%
USPH U S PHYSICAL THERAPY INC /NV $1.18B 55.9x 16.3%
SRTA Strata Critical Medical, Inc. $470.6M 10.6x 34.3%
DCGO DocGo Inc. $39.8M -47.7%